Fåhraeus Startup and Growth

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

Speqta is a performance marketing company that owns and operates an advertising network as well as several digital products and services.

Yazen is a digital healthcare provider focused on offering customized weight loss programs primarily for middle-aged men dealing with obesity and related health issues, including potential testosterone deficiencies. The platform connects users with a multidisciplinary team of professionals, such as doctors, psychologists, dietitians, and personal trainers, to develop personalized weight management plans. By analyzing individual data, Yazen provides recommendations for lifestyle changes and, when necessary, medication to enhance both physical and mental well-being.

Airsonett is a medical device company focused on developing non-pharmaceutical treatments for allergic asthma and eczema. Its flagship product, the Air4, utilizes patented Temperature-controlled Laminar Airflow (TLA) technology to significantly reduce allergens and airborne irritants in a patient's breathing zone during rest and sleep. This innovative home medical device aims to provide relief for individuals suffering from allergic asthma and atopic eczema, primarily serving patients in Sweden and the UK. By offering a non-invasive solution, Airsonett addresses the need for effective prophylactic treatments without relying on traditional medication.

Melius Pharma is a pharmaceutical company dedicated to developing new treatments for interstitial lung diseases. The company specializes in addressing severe conditions with significant unmet clinical needs, particularly focusing on chronic cough associated with idiopathic pulmonary fibrosis. Melius Pharma aims to provide effective treatment solutions for healthcare professionals managing these challenging respiratory conditions.

Nygen Analytics specializes in providing cloud-based solutions for the analysis of single-cell genomic data. The company develops innovative tools and services aimed at facilitating sustainable and cost-effective genomics research. By focusing on user-centric applications, Nygen Analytics addresses critical bottlenecks in the field, enabling researchers to conduct more efficient analyses and derive meaningful insights from complex genomic data.

Saveggy develops a bio-based edible vegan coating for fruit and vegetables eliminating plastic while keeping its protecting properties.

Moroxite F develops a new fracture treatment method that improves the anchoring of implants in osteoporosis.

Brick is an app that solves the problem of electronics running out of battery. Download our app and find the nearest Brick station on the map, then rent a power bank (with cables) to charge your phone, tablet, headphones or whatever it is that is running out of battery. Return the power bank to any Brick station so that you can charge on the go. Stay in charge.

Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, specifically advanced or metastatic renal cancer. The company is focused on the compound orellanine, a toxin derived from certain mushroom species, which has demonstrated potent anti-tumor activity. Oncorena's primary objective is to confirm the efficacy and clinical benefits of orellanine in targeting renal proximal tubular epithelial cells that have transformed into cancer cells and formed metastases. By harnessing the selective properties of this compound, Oncorena aims to provide effective pharmacological solutions for patients suffering from advanced kidney cancer.